MENU
+Compare
FATE
Stock ticker: NASDAQ
AS OF
Jul 8, 04:59 PM (EDT)
Price
$1.09
Change
+$0.04 (+3.77%)
Capitalization
124.95M

FATE Fate Therapeutics Forecast, Technical & Fundamental Analysis

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States... Show more

Industry: #Biotechnology
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for FATE with price predictions
Jul 07, 2025

FATE in +9.62% Uptrend, advancing for three consecutive days on July 01, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where FATE advanced for three days, in of 257 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Aroon Indicator entered an Uptrend today. In of 164 cases where FATE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for FATE moved out of overbought territory on June 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on June 16, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on FATE as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for FATE turned negative on June 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 59 similar instances when the indicator turned negative. In of the 59 cases the stock turned lower in the days that followed. This puts the odds of success at .

FATE moved below its 50-day moving average on June 20, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for FATE crossed bearishly below the 50-day moving average on June 26, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FATE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

FATE broke above its upper Bollinger Band on June 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.433) is normal, around the industry mean (16.718). P/E Ratio (0.000) is within average values for comparable stocks, (58.312). FATE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.371). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (9.643) is also within normal values, averaging (263.500).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. FATE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

FATE is expected to report earnings to rise 7.09% to -34 cents per share on July 30

Fate Therapeutics FATE Stock Earnings Reports
Q2'25
Est.
$-0.34
Q1'25
Beat
by $0.07
Q4'24
Est.
$-0.44
Q3'24
Beat
by $0.02
Q2'24
Beat
by $0.13
The last earnings report on May 13 showed earnings per share of -31 cents, beating the estimate of -38 cents. With 741.09K shares outstanding, the current market capitalization sits at 124.95M.
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12278 Scripps Summit Drive
Phone
+1 858 875-1800
Employees
220
Web
https://www.fatetherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MTHRY6.530.12
+1.87%
M3, Inc.
BLWYF35.78N/A
N/A
Bellway Plc.
MKKOF12.96N/A
N/A
Marimekko Oyj
NRDE1.35N/A
N/A
NU RIDE INC
CRYM0.03N/A
-0.55%
Cryomass Technologies Inc.

FATE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
+2.83%
ALLO - FATE
57%
Loosely correlated
+3.45%
CRBU - FATE
57%
Loosely correlated
+15.11%
CRSP - FATE
56%
Loosely correlated
+7.09%
RXRX - FATE
56%
Loosely correlated
+8.72%
CCCC - FATE
52%
Loosely correlated
+12.50%
More